IL92952A - R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them - Google Patents

R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL92952A
IL92952A IL9295290A IL9295290A IL92952A IL 92952 A IL92952 A IL 92952A IL 9295290 A IL9295290 A IL 9295290A IL 9295290 A IL9295290 A IL 9295290A IL 92952 A IL92952 A IL 92952A
Authority
IL
Israel
Prior art keywords
propargyl
aminoindan
pai
mao
pharmaceutical composition
Prior art date
Application number
IL9295290A
Other languages
English (en)
Other versions
IL92952A0 (en
Inventor
Moussa B H Youdim
John P M Finberg
Ruth Levy
Jeffrey Sterling
David Lerner
Tirtsah Berger-Paskin
Haim Yellin
Original Assignee
Teva Pharma
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11060756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL92952(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Technion Res & Dev Foundation filed Critical Teva Pharma
Priority to IL9295290A priority Critical patent/IL92952A/en
Publication of IL92952A0 publication Critical patent/IL92952A0/xx
Priority to HU051/90A priority patent/HU215451B/hu
Priority to AU67724/90A priority patent/AU630772B2/en
Priority to IE437690A priority patent/IE62371B1/en
Priority to CA002031714A priority patent/CA2031714C/fr
Priority to ZA909997A priority patent/ZA909997B/xx
Priority to RO146581A priority patent/RO107552B1/ro
Priority to JP2409285A priority patent/JP2987453B2/ja
Priority to EP91100081A priority patent/EP0436492B1/fr
Priority to AT91100081T priority patent/ATE106860T1/de
Priority to ES91100081T priority patent/ES2057604T3/es
Priority to DE69102288T priority patent/DE69102288T2/de
Priority to SU914894485A priority patent/RU2001614C1/ru
Priority to DK91100081.8T priority patent/DK0436492T3/da
Priority to SK6-91A priority patent/SK280742B6/sk
Priority to CS19916A priority patent/CZ288222B6/cs
Priority to US08/063,455 priority patent/US5387612A/en
Priority to US08/198,205 priority patent/US5457133A/en
Priority to US08/255,046 priority patent/US5453446A/en
Publication of IL92952A publication Critical patent/IL92952A/en
Priority to DE200512000045 priority patent/DE122005000045I1/de
Priority to US08/411,398 priority patent/US5532415A/en
Priority to US08/446,439 priority patent/US5744500A/en
Priority to US08/458,645 priority patent/US5668181A/en
Priority to US08/459,402 priority patent/US5576353A/en
Priority to US08/470,161 priority patent/US5786390A/en
Priority to US08/466,069 priority patent/US5519061A/en
Priority to US08/465,787 priority patent/US5599991A/en
Priority to US08/466,250 priority patent/US5891923A/en
Priority to HK98107147.0A priority patent/HK1008017B/en
Priority to US10/305,478 priority patent/US6956060B2/en
Priority to US11/155,864 priority patent/US20060094783A1/en
Priority to NL300206C priority patent/NL300206I1/nl
Priority to LU91195C priority patent/LU91195I2/fr
Priority to US11/595,726 priority patent/US20070100001A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL9295290A 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them IL92952A (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
IL9295290A IL92952A (en) 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
HU051/90A HU215451B (hu) 1990-01-03 1990-12-04 R(+)-N-propargil-1-amino-indán, a vegyületet tartalmazó gyógyászati készítmények és előállításuk
AU67724/90A AU630772B2 (en) 1990-01-03 1990-12-04 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IE437690A IE62371B1 (en) 1990-01-03 1990-12-04 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them.
CA002031714A CA2031714C (fr) 1990-01-03 1990-12-06 R-enantiomeres de n-propargyl-1-amino-indane; preparation et compositions pharmaceutiques qui en renferment
ZA909997A ZA909997B (en) 1990-01-03 1990-12-12 R-enantiomers of n-propargyl-1-aminoindan compounds,their preparation and pharmaceutical compositions containing them
RO146581A RO107552B1 (ro) 1990-01-03 1990-12-18 Derivat de 1-aminoindan, procedeu de obtinere si compozitii farmaceutice care continind acest derivat
JP2409285A JP2987453B2 (ja) 1990-01-03 1990-12-28 Ｎ−プロパルギル−１−アミノインダン化合物のｒ（＋）−鏡像体、それらの製造法およびそれらを含有する薬剤組成物
DK91100081.8T DK0436492T3 (da) 1990-01-03 1991-01-02 R-Enantiomere af N-propargyl-1-aminoindanforbindelser, fremstilling deraf samt farmaceutiske præparater indeholdende disse forbindelser
EP91100081A EP0436492B1 (fr) 1990-01-03 1991-01-02 R-Enantiomère de N-propargyl-1-aminoindane, son préparation et composition pharmaceutique le contenant
SU914894485A RU2001614C1 (ru) 1990-01-03 1991-01-02 R (+)-N-Пропаргил-1-аминоиндан и его фармацевтически пригодные кислотно-аддитивные соли и фармацевтическа композици , обладающа ингибирующей B-форму фермента моноаминооксидазы активностью
AT91100081T ATE106860T1 (de) 1990-01-03 1991-01-02 R-enantiomer von n-propargyl-1-aminoindan, dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
ES91100081T ES2057604T3 (es) 1990-01-03 1991-01-02 Enantiomero r de n-propargil-1-aminoindano, su preparacion y composiciones farmaceuticas que lo contienen.
DE69102288T DE69102288T2 (de) 1990-01-03 1991-01-02 R-Enantiomer von N-Propargyl-1-aminoindan, dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen.
SK6-91A SK280742B6 (sk) 1990-01-03 1991-01-03 R(+)-n-propargyl-1-aminoindán, spôsob jeho príprav
CS19916A CZ288222B6 (en) 1990-01-03 1991-01-03 R-Enantiomers of N-propargyl-1-aminoindane compounds, process of their preparation and pharmaceutical preparations in which they are comprised
US08/063,455 US5387612A (en) 1990-01-03 1993-05-18 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
US08/198,205 US5457133A (en) 1990-01-03 1994-02-17 R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US08/255,046 US5453446A (en) 1990-01-03 1994-06-07 Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
DE200512000045 DE122005000045I1 (de) 1990-01-03 1994-07-14 R-Enantiomer von N-Propargyl-1-aminoindan, dessen Herstellung und dieses enthaltende pharmazeutischeZusammensetzungen.
US08/411,398 US5532415A (en) 1990-01-03 1995-03-28 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US08/446,439 US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US08/458,645 US5668181A (en) 1990-01-03 1995-06-02 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the treatment of depression
US08/459,402 US5576353A (en) 1990-01-03 1995-06-02 Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds
US08/470,161 US5786390A (en) 1990-01-03 1995-06-06 Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
US08/466,069 US5519061A (en) 1990-01-03 1995-06-06 R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
US08/465,787 US5599991A (en) 1990-01-03 1995-06-06 Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan
US08/466,250 US5891923A (en) 1990-01-03 1995-06-06 R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia
HK98107147.0A HK1008017B (en) 1990-01-03 1998-06-27 R-enantiomer of n-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it
US10/305,478 US6956060B2 (en) 1990-01-03 2002-11-27 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US11/155,864 US20060094783A1 (en) 1990-01-03 2005-06-17 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
NL300206C NL300206I1 (nl) 1990-01-03 2005-08-16 R-enantiomeer van N-propargyl-1-aminoindaan, de bereiding daarvan en farmaceutische preparaten die dit bevatten.
LU91195C LU91195I2 (fr) 1990-01-03 2005-08-17 Rasagiline et ses sels pharmaceutiquement acceptables (AZILECT)
US11/595,726 US20070100001A1 (en) 1990-01-03 2006-11-10 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL9295290A IL92952A (en) 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL92952A0 IL92952A0 (en) 1990-09-17
IL92952A true IL92952A (en) 1994-06-24

Family

ID=11060756

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9295290A IL92952A (en) 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (10) US5387612A (fr)
EP (1) EP0436492B1 (fr)
JP (1) JP2987453B2 (fr)
AT (1) ATE106860T1 (fr)
AU (1) AU630772B2 (fr)
CA (1) CA2031714C (fr)
CZ (1) CZ288222B6 (fr)
DE (2) DE69102288T2 (fr)
DK (1) DK0436492T3 (fr)
ES (1) ES2057604T3 (fr)
HU (1) HU215451B (fr)
IE (1) IE62371B1 (fr)
IL (1) IL92952A (fr)
LU (1) LU91195I2 (fr)
NL (1) NL300206I1 (fr)
RO (1) RO107552B1 (fr)
RU (1) RU2001614C1 (fr)
SK (1) SK280742B6 (fr)
ZA (1) ZA909997B (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1995018617A1 (fr) * 1994-01-10 1995-07-13 Teva Pharmaceutical Industries Ltd. Derives de 1-amino-indane et leurs compositions
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
PT814789E (pt) * 1995-03-02 2003-09-30 Scherer Technologies Inc R P Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b
US5679715A (en) * 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
US5646188A (en) * 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
AU771490B2 (en) * 1995-09-20 2004-03-25 Teva Pharmaceutical Industries Ltd. Stable compositions containing N-propargyl-1-aminoidan
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
PT966435E (pt) * 1996-12-18 2005-06-30 Yissum Res Dev Co Derivados aminoindano
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US8048875B1 (en) * 1997-02-24 2011-11-01 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
WO1998036733A2 (fr) 1997-02-24 1998-08-27 Michael Albert Kamm Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US5866547A (en) * 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) * 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US6376545B1 (en) 1998-11-10 2002-04-23 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing L-DOPA ethyl ester
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
WO2001030339A1 (fr) 1999-10-27 2001-05-03 Teva Pharmaceutical Industries, Ltd. Utilisation de derives de 1-aminoindan pour le traitement de la manie liée à la psychose maniacodépressive
RU2170576C1 (ru) * 1999-11-15 2001-07-20 Государственное учреждение науки Институт токсикологии Гидрохлориды замещенных ацетиленовых аминоспиртов, обладающие антигалоперидоловой активностью
US6548484B1 (en) 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
IL141690A (en) * 2001-02-27 2004-06-20 Isp Finetech Ltd Process for preparation of rasagiline and its salts
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
DK1567152T3 (da) 2002-11-15 2013-10-07 Teva Pharma Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
EP1426049B1 (fr) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Administration par iontophorèse de rotigotine pour traiter la maladie de Parkinson
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (fr) 2003-11-25 2009-03-25 Technion Res & Dev Foundation Compositions et procedes pour traiter des troubles et des maladies cardiovasculaires
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
WO2006014968A2 (fr) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Nitroxydes propargyle et nitroxydes indanyle et leur utilisation pour traiter les maladies et les troubles neurologiques
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
JP2008531546A (ja) * 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス
JP5738509B2 (ja) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
US8022104B2 (en) * 2005-02-24 2011-09-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulations of ladostigil tartrate
CA2620476A1 (fr) * 2005-06-02 2006-12-07 Jenrin Discovery Inhibiteurs de la mao-b utilises pour traiter l'obesite
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1956904B1 (fr) 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Ladostigil a faible dose pour le traitement du déficit cognitif léger
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
CN1990455B (zh) * 2005-12-29 2011-06-08 北京德众万全医药科技有限公司 一种简单、新颖的茚衍生物的制备方法
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
WO2007126898A2 (fr) * 2006-03-31 2007-11-08 Teva Pharmaceutical Industries, Ltd. Utilisation de ladostigil pour le traitement de la schizophrénie
WO2007117431A2 (fr) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Utilisation de rasagiline pour le traitement du syndrome des jambes sans repos
EP2042480B1 (fr) * 2006-07-18 2013-05-01 Astellas Pharma Inc. Dérivé d'aminoindane ou sel de celui-ci
EP1892233A1 (fr) * 2006-08-18 2008-02-27 Ratiopharm GmbH De nouveaux sels de la substance active rasagiline
NZ577623A (en) * 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP1987816A1 (fr) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate d'un sel de rasagiline en combinaison avec un agent inactive soluble dans l'eau
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
JP5425806B2 (ja) * 2007-12-24 2014-02-26 シプラ・リミテッド プロパルギル化アミノインダン誘導体の合成方法
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
EP2271612B1 (fr) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Particules de mésylate de rasagiline et leur procédé de préparation
WO2009141737A2 (fr) * 2008-05-23 2009-11-26 Medichem, S.A. Nouveau procédé d'obtention d'un dérivé de mésylate d'aminoindane
CN102123980B (zh) 2008-06-02 2014-05-07 基因里克斯(英国)有限公司 用于制备对映异构纯胺的方法
EP2280929B1 (fr) * 2008-06-02 2018-01-31 Generics [UK] Limited Methode amelioree de preparation de rasagiline
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
EA201170018A1 (ru) * 2008-06-13 2011-08-30 Тева Фармасьютикал Индастриз, Лтд. Разагилин для изменения течения болезни паркинсона
EP2299993A4 (fr) * 2008-06-19 2014-08-20 Teva Pharma Procédé de purification de la base de la rasagiline
CN102065853A (zh) * 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
EP2328861A2 (fr) 2008-07-11 2011-06-08 Synthon BV Polymorphes de chlorhydrate de rasagiline
IT1392914B1 (it) * 2009-01-22 2012-04-02 Dipharma Francis Srl Procedimento per la preparazione di (r)-n-propargil-1-amminoindano e suoi sali
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
EP2181980A1 (fr) 2008-10-28 2010-05-05 Chemo Ibérica, S.A. Procédé pour la préparation de (R)-1-aminoindanes
EP2358658A4 (fr) 2008-11-20 2012-11-14 Reddys Lab Ltd Dr Préparation de rasagiline et de ses sels
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP2218444A3 (fr) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Formulation de rasagiline à libération retardée
WO2010100219A2 (fr) 2009-03-05 2010-09-10 Sandoz Ag Composition pharmaceutique contenant du (1r)-méthanesulfonate de 1h-indén-1-amine-2,3-dihydro-n-2-propynyle
CA2767592A1 (fr) 2009-07-09 2011-01-13 Ratiopharm Gmbh Sels de rasagiline et leurs preparations pharmaceutiques
WO2011048612A2 (fr) * 2009-10-14 2011-04-28 Glenmark Generics Limited Procédé d'élaboration d'aminoindanes propargylés y compris un sel pharmaceutiquement acceptable correspondant
EP2325159A1 (fr) * 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Nouveaux sels de rasagiline
US8741962B2 (en) 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
EP2939669A1 (fr) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-céto-n-propargyl-1-aminoindane
US20120269871A1 (en) 2009-12-30 2012-10-25 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (fr) * 2010-02-02 2011-08-11 Glenmark Generics Limited Sels de rasagiline et procédés de preparation de ces derniers
EP2531181B1 (fr) 2010-02-03 2019-04-10 Pharma Two B Ltd. Formulations à libération prolongée de rasagiline et leurs utilisations
WO2011121607A2 (fr) 2010-03-29 2011-10-06 Cadila Healthcare Limited Composé de rasagiline et sels pharmaceutiquement acceptables de celui-ci
CN108186611A (zh) 2010-04-30 2018-06-22 帝国制药美国公司 丙炔基氨基茚满透皮组合物
EP2389927A1 (fr) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations pharmaceutiques de rasagiline
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
MX2013004598A (es) * 2010-10-26 2013-07-17 Teva Pharma Rasagilina enriquesida con deuterio.
US8901352B2 (en) 2011-01-13 2014-12-02 Nobel Ilaç Sanayii Ve Ticaret A.S. Method for the synthesis of rasagiline
EP2681186B1 (fr) 2011-03-03 2016-05-11 Synthon BV Procédé de résolution de 1-aminoindane
WO2012129429A2 (fr) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
WO2012153349A2 (fr) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline et ses sels pharmaceutiquement acceptables
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
WO2013070526A1 (fr) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Méthodes pour le traitement de tumeurs de la peau
EP2610239A1 (fr) 2012-01-02 2013-07-03 Dr. Reddy's Laboratories Ltd. Préparation de rasagiline hémitartrate
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
EP2827848B1 (fr) 2012-03-21 2016-04-27 Synthon BV Compositions pharmaceutiques stables comprenant des sels de la rasiligine
WO2013175493A1 (fr) 2012-04-09 2013-11-28 Cadila Healthcare Limited Compositions pharmaceutiques orales stables
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
US9205061B2 (en) 2012-11-02 2015-12-08 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
ES2524865T1 (es) 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
ES2502140T1 (es) 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
US20160022572A1 (en) * 2013-03-13 2016-01-28 N To B Ltd. Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
WO2015136515A1 (fr) * 2014-03-13 2015-09-17 Abital Pharma Pipelines Ltd. Procédés, compositions et dispositifs destinés au traitement des symptômes moteurs et dépressifs associés à la maladie de parkinson
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
FR1366728A (fr) * 1961-03-01 1964-07-17 Roussel Uclaf Nouveaux dérivés du gonane et leur procédé de préparation
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1037014A (en) * 1963-08-02 1966-07-20 Aspro Nicholas Ltd Derivatives of 1-aminoindane
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US3513249A (en) * 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
EP0252290B1 (fr) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Compositions pharmaceutiques contenant le lévodopa méthyl ester, leur préparation et leurs applications thérapeutiques
JPH03176457A (ja) * 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
HU908051D0 (en) 1991-06-28
JP2987453B2 (ja) 1999-12-06
EP0436492A2 (fr) 1991-07-10
US5387612A (en) 1995-02-07
SK280742B6 (sk) 2000-07-11
EP0436492A3 (en) 1991-11-13
CA2031714C (fr) 1998-08-25
US5786390A (en) 1998-07-28
EP0436492B1 (fr) 1994-06-08
IL92952A0 (en) 1990-09-17
HK1008017A1 (en) 1999-04-30
AU6772490A (en) 1991-07-04
ES2057604T3 (es) 1994-10-16
DE69102288D1 (de) 1994-07-14
DE69102288T2 (de) 1995-02-09
US5519061A (en) 1996-05-21
US5891923A (en) 1999-04-06
CA2031714A1 (fr) 1991-07-04
LU91195I2 (fr) 2005-10-17
US5668181A (en) 1997-09-16
US5576353A (en) 1996-11-19
US5599991A (en) 1997-02-04
DK0436492T3 (da) 1994-07-11
US5453446A (en) 1995-09-26
ZA909997B (en) 1991-10-30
CS691A3 (en) 1991-08-13
DE122005000045I1 (de) 2005-12-22
IE62371B1 (en) 1995-01-25
CZ288222B6 (en) 2001-05-16
AU630772B2 (en) 1992-11-05
RO107552B1 (ro) 1993-12-30
US5457133A (en) 1995-10-10
JPH03294248A (ja) 1991-12-25
US5532415A (en) 1996-07-02
RU2001614C1 (ru) 1993-10-30
IE904376A1 (en) 1991-07-03
HU215451B (hu) 2000-10-28
ATE106860T1 (de) 1994-06-15
NL300206I1 (nl) 2005-10-03
HUT59376A (en) 1992-05-28

Similar Documents

Publication Publication Date Title
CA2031714C (fr) R-enantiomeres de n-propargyl-1-amino-indane; preparation et compositions pharmaceutiques qui en renferment
EP0812190B1 (fr) R-enantiomere de n-propargyl-1-amino-indane pour le traitement des maladies diverses et son mesylate, esylate et sulfate
AU699090B2 (en) Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
HK1008017B (en) R-enantiomer of n-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
KB Patent renewed
EXTP Application for extension order is pending
KB Patent renewed
PEL Intention of commissioner to extend period of protection
EXTG Extension of patent term granted
EXTN Extension order renewed
EXTN Extension order renewed
EXTN Extension order renewed
EXTN Extension order renewed